We have established a panel of nine immortal cell lines from T cell malignancies which arose in mice transgenic for the SCL and LMO1 genes. Cells from the primary malignancies initially grew very slowly in vitro, loosely attached to a stromal layer, before gaining the ability to proliferate independently. Upon gaining the ability to proliferate in the absence of a stromal layer, these cell lines grew rapidly, doubling every 14-23 h, to a very high density, approaching 10 7 cells/ml. Whereas the tumors which arise in SCL/LMO1 double transgenic mice are typically diploid or pseudodiploid, the cell lines were all grossly aneuploid, suggesting the possibility that additional genetic events were selected for in vitro. Given that SCL and LMO1 gene activation are both commonly seen in human patients with T cell acute lymphoblastic leukemia, these cell lines may be a useful in vitro model for the human disease. Leukemia (2001) 15, 141-147.
Introduction
The analysis of immortal cell lines derived from primary hematopoietic malignancies has been a valuable tool in understanding the nature of many hematopoietic malignancies. [1] [2] [3] Immortal cell lines provide an inexhaustible source of homogeneous, defined malignant cells free from contamination with normal blood elements. Conversely, one of the most prominent disadvantages of using malignant cell lines as a model for primary malignancy is the possibility that the cells which become immortalized were selected for their ability to grow in vitro, and that the immortalized cell lines may not be truly representative of the primary malignancy. [1] [2] [3] Two of the genes commonly activated in patients with T cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma are SCL/tal (hereafter SCL) and LMO1. 4, 5 It has recently been shown that SCL and LMO1 (or the closely related LMO2) proteins collaborate to induce T cell leukemia or lymphoma in transgenic mice. [6] [7] [8] [9] Several lines of evidence, including in vitro and in vivo assays of reporter genes, suggest that SCL and LMO1 exert their leukemogenic action via inhibition of E2A and or HEB, which are E-proteins required for normal T cell development.
9-14 SCL exists as two distinct isoforms, a full-length form with an apparent molecular mass of 42-44 kDa, and an amino-terminal truncated version which has an apparent molecular mass of 24-26 kDa. 15 Transgenic mice expressing either isoform of SCL co-operate equally well with LMO1 to induce T-ALL, suggesting that the aminoterminal portion of SCL, which contains a transactivation domain, is dispensable for its leukemogenic effect. 8, 9 As part of an ongoing study of the leukemogenic action of ectopically expressed SCL, we have established a series of immortal cell lines derived from T cell malignancies which arose in mice that are transgenic for SCL and LMO1. We have characterized these immortal cell lines in terms of in vitro growth characteristics, immunophenotype, leukemogenicity and clonality. Since SCL and LMO1 activation are commonly seen in association with human T cell acute lymphoblastic leukemia, we feel that these cell lines will provide a valuable resource which can be used to study the leukemogenic action of SCL and LMO1.
Materials and methods

Establishment of cell lines
Generation of transgenic mice which express SCL and LMO1 in the thymus has been described elsewhere. 8, 9, 16 SCL/LMO1 transgenic mice were sacrificed when they showed clinical signs of malignant disease. These signs typically consisted of peripheral lymphadenopathy, splenomegaly, and tachypnea (caused by a large mediastinal mass). Tumors were dissected and immediately placed in ice-cold Iscove's modified Dulbecco's medium (IMDM) supplemented with 15% fetal bovine serum (FBS), L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 g/ml) (all from Life Technologies, Grand Island, NY, USA). Tumor cells, usually from the mediastinal mass, were disaggregated using a loose-fitting ground glass homogenizer (Kontes type; VWR Scientific, Rochester, NY, USA). The resulting single cell suspensions were placed in 75-cm tissue culture flasks (Becton Dickinson, Franklin Lakes, NJ, USA) containing IMDM supplemented as above. Half of the medium in each flask was removed and replaced with fresh IMDM complete medium once or twice a week. The cell lines were screened for evidence of mycoplasma infection using a PCR detection assay (Mycoplasma Plus, Stratagene, La Jolla, CA, USA) and found to be uninfected.
Immunophenotype
Cells growing in log phase in vitro, or fresh suspensions of tumor cells prepared as described above were washed and resuspended in ice-cold Dulbecco's phosphate-buffered saline without calcium chloride and magnesium chloride (PBS). All subsequent procedures were done at 4°C. Cells were immunophenotyped using conjugated monoclonal antibodies and standard techniques. Briefly, 10 6 cells were placed into 12 × 75 mm tubes, blocked for 15 min with 10 g of rat and/or hamster IgG, and stained with the indicated antibody conjugate for 45 min. The conjugates used were CD3 TC, CD4 FITC, CD8 R-PE, CD25 R-PE, CD44 FITC and TCR␤ TC (Caltag, Burlingame, CA, USA). The cells were then collected by centrifugation at 200 g, washed twice with PBS and fixed Leukemia with 1% paraformaldehyde. At least 5000 events were analyzed by FACScan (Becton Dickinson).
Cell cycle and ploidy analysis
Cells were washed as above, fixed with 70% ethanol, and stained with 1 ml of 50 g/ml propidium iodide (PI) in 0.1% sodium citrate containing 0.37% Nonidet P-40 (NP40) and 20 g/ml RNase-A (all from Sigma, St Louis, MO,USA) for at least 30 min. Cells were kept at 4°C for no more than 24 h and resuspended in fresh propidium stain immediately before FACScan analysis. At least 15 000 events were analyzed using the Modfit software package. For ploidy analysis, fixed chick RBC and normal mouse splenocytes were used as reference controls.
In vivo tumorigenicity assays
Exponential growth phase cells (5-10 × 10 6 ) were washed once with sterile PBS, collected by centrifugation at 1000 g, and resuspended in sterile PBS prior to intraperitoneal injection into immunodeficient nu/nu mice (Harlan Sprague Dawley, Indianapolis, IN, USA), in a total volume of 0.5 ml. The mice were evaluated for clinical symptoms of malignancy (weight loss, tachypnea or palpable lymphadenopathy), and sacrificed when an obvious tumor burden was detected. Animals were autopsied and tumor tissue harvested for subsequent analysis.
In vitro viability and growth
For serum deprivation experiments, exponential growth phase cells were washed twice in IMDM supplemented with 0.1% FBS and seeded in 25-cm 2 flasks (Becton Dickinson) at a concentration of 1 × 10 5 per ml, also in IMDM supplemented with 0.1% FBS. Cell counts and cell viability were determined using 0.18% trypan blue dye exclusion (Life Technologies). For standard cell growth kinetics, exponential growth phase cells were seeded at a concentration of 1 × 10 4 per ml and counted on a daily basis as described above.
Nucleic acid manipulations
Genomic DNA was isolated from tumors and cell lines as previously described. 8 Southern blots were performed as previously described. 17 Probes used in this study were human T cell receptor (TCR) C␤2, (a gift of Dr Ilan Kirsch, National Cancer Institute, Bethesda, MD,USA), SCL, 15 and LMO1. 18 
Cloning of TCR␤ gene rearrangements by RT-PCR
We used an adaptation of a previously described method 19 to clone TCR␤ gene rearrangements. Briefly, first-strand cDNA was synthesized from 1 g of total RNA using Superscript II reverse transcriptase (Life Technologies), following the manufacturer's recommended protocol. The quality of the cDNA was assessed by amplification of ␤-actin mRNA, using sense (5Ј-GTGGGCCGCTCTAGGCACCAA-3Ј) and antisense (5Ј-CTCTTTGATGTCACGCACGATTTC-3Ј) primers. TCR␤ mRNA was amplified using a degenerate V␤ region primer (5Ј-TAAGCGGCCGCATGSLYTGGTAYWXXCAG-3Ј; S = G or T; L = A, G or T; Y = C or T; W = A or C; X = A or G), and a C␤ primer (5Ј-CCCACCAGCTCAGCTCCACGTGG-3Ј) whose sequence was identical for both C␤1 and C␤2. The cycling parameters were 40 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min, followed by a terminal extension of 10 min at 72°C. The PCR products were gel-purified and subcloned into pGEM T-Easy (Promega, Madison, WI, USA). Individual plasmid clones were isolated for sequence analysis.
Results
Establishment of immortal cell lines from SCL/LMO1 tumors
We attempted to establish cell lines from approximately 40 primary T cell malignancies arising in SCL/LMO1 double transgenic mice, as described in the methods section. Approximately one half of the cells never grew well in vitro, and one fourth of the cultures were discarded due to bacterial or fungal contamination. However, we were able to establish immortal cell lines for nine SCL/LMO1 tumor samples which were placed in culture. A distinct growth pattern was noted as the cell lines became established. As described in the Methods section, disaggregated tumor cells were placed in tissue culture flasks, and within 1-2 weeks, small colonies displaying two distinct cellular morphologies were noted. During this early phase of cell line growth, small round cells (which morphologically appeared similar to lymphoblasts on Wright stain, data not shown) can be seen as cellular aggregates loosely attached to a densely adherent stromal cell layer. During this time period, cells which became detached (for example, by vigorous shake off) were unable to proliferate when seeded in fresh media and transferred to a new flask. Following this initial phase, which generally lasted 1-3 months, the small round cells growing as loose aggregates began to expand more rapidly, and grow as either single cells or small aggregates (8-20 cells) in suspension. At this point in time, the suspension cells were able to proliferate independently of the adherent stromal layer, and after one to five passages of smoldering growth, these cells began to expand at a rapid rate. The established cell lines were routinely passaged on a weekly basis with serial dilutions of up to 1:2500.
All of the cell lines described here have been in continuous culture in vitro for 21-41 months. We have been able to successfully thaw and expand cells from vials that have been viably frozen Ͼ16 months. Three of the cell lines established were derived from mice that expressed the full-length SCL protein (6781/3, 6812/2, 6913/1), while six were established from transgenic mice which expressed the truncated SCL protein (6472/3, 6600/1, 6605/4, 6645/4, 7114/1, 7298/2).
Immunophenotype of SCL/LMO1 cells lines
The immunophenotypes of the SCL/LMO1 cell lines are summarized in Table 1 . These cell lines were heterogeneous with respect to expression of the antigens studied, although all but one (6472/3) were at least 27% positive for TCR␤ expression. In contrast to the primary tumors, which were often CD4 + /CD8 + (Ref . 8 and Table 1 ), the cell lines had often lost expression of CD4 (8/9 being CD4 negative) and, less commonly, CD8. 
Growth characteristics of SCL/LMO1 cell lines
The SCL/LMO1 cell lines grew to extraordinarily high densities ranging from 2 to 9 × 10 6 /ml cells in vitro. The average doubling time was 19 h, with a range of 14-23 h. Shortly after reaching their peak density, the cells began to die, showing morphologic (nuclear condensation and fragmentation) and molecular (oligonucleosomal ladders) signs consistent with apoptosis (data not shown). We used propidium iodide staining to assess both DNA index (ploidy) and cell cycle phase of the cell lines. Table 2 demonstrates that a large fraction of the cells was rapidly proliferating, with 35-56% of the cells in either S or G2-M phase. The DNA index ranged from 1.21 to 1.59, demonstrating that the cell lines were all aneuploid at the time of this analysis (Table 3) . By way of comparison, we were able to assess DNA ploidy of the original malignancy from viably frozen cells in three cases (6605/4, 6812/2 and 7298/2); in each case the DNA index was 1 or 1.01, indicating these three original tumors were either diploid or pseudodiploid (data not shown). In addition, the DNA index for eight additional fresh tumor samples was between 0.97 and 1.03 (Table 3 ), indicating that primary tumors from SCL/LMO1 The percentage of cells in G0/G1, S and G2/M phases are indicated.
Leukemia transgenic mice are either diploid or pseudodiploid, and that progression to aneuploidy occurs during passage in vitro.
To determine the requirement for growth factors present in fetal bovine serum (FBS), we attempted to grow these cell lines in no serum or low serum. Whereas none of the cell lines proliferated in the absence of serum (data not shown), one of the nine cell lines (6605/4) grew quite well, to cell densities exceeding 4 × 10 5 cells/ml, in media containing only 0.1% FBS. Although we routinely passaged the cell lines in media containing 15% FBS, six of the nine cell lines were able to proliferate, to densities of 3-9 × 10 5 cells/ml, in IMDM containing only 0.5% FBS (data not shown).
SCL/LMO1 cell lines are oncogenic in vivo
To assess the oncogenicity of these cell lines, we attempted to transfer them into immunodeficient nu/nu mice. All of these cell lines produced aggressive T cell tumors in nu/nu mice. The clinical characteristics of the tumors arising in nude mice are shown in Table 4 ; not unexpectedly, infiltration of lymphoid organs and ascites were commonly found. 
Clonal TCR␤ gene rearrangements in SCL/LMO1 cell lines
We used TCR␤ gene rearrangements to assess clonality in the tumors that developed in the transplanted mice. Surprisingly, the pattern of clonal TCR␤ gene rearrangements seen in the tumors which developed in the transplanted mice did not always correlate with those seen in the original malignancies (Figure 1a and b) . This finding prompted us to analyze the TCR␤ gene rearrangements in the primary malignancies, cell lines, and transplanted malignancies more closely. Figure 1a shows that the initial tumor from animal 6605/4 had four clonal TCR␤ gene rearrangements, most likely due to two independent clones with biallelic rearrangements. However, as the cell line became established, one clone, which displayed biallelic rearrangements of approximately 5 and 7.5 kb, predominates. This clone underwent no further rearrangements when transplanted into nude mice. A similar situation can be seen with cell line 6781/3 (Figure 1b) . At diagnosis, an SstI digest shows that the predominant clone has two comigrating bands at 11 kb, while a minor clone has two bands at ෂ7.5 and 8 kb. However, after several months in tissue culture, the minor clone begins to predominate, and the predominant clone at diagnosis becomes overgrown and is no longer detectable by Southern blot. In contrast, cell lines 7114/1 and 6812/3 each had one rearranged allele which was stable 145 . clones  2  3  2  4  4  3  1  V region  V10S1  V8S3  V14S1  V6S1  V8S3  V6S1  V8S2  D region  D2  D2  D2  D1  D2  D1  D2  J region  J2S5  J2S7  J2S7  J2S5  J2S5  J1S1  J2S7  C region  C2  C2  C2  C2  C2  C1  C2  In frame  yes  yes  yes  yes  yes  yes  yes   a Number of independent plasmid clones sequences which displayed the indicated VDJ rearrangement.
(clonal SstI fragments of 4 and 13 kb, respectively), while the other allele showed evidence of ongoing TCR␤ gene rearrangement as the cell line became established. In all, eight of the nine cell lines showed a pattern of TCR␤ gene rearrangements after several months in culture that was in some way different to that seen at diagnosis. In some cases, as described above, this evolution was probably due to a biclonal tumor at initial diagnosis, while in other cases, the evolution was probably the result of ongoing TCR␤ gene rearrangement within the same malignant clone. Northern blot analysis demonstrated that TCR␤ mRNA was expressed in all of the SCL/LMO1 cell lines (data not shown). Therefore, we used an RT-PCR assay to clone the TCR␤ gene rearrangements from several of the SCL/LMO1 cell lines. The results are summarized in Table 5 . In all but one of the cell lines analyzed, we were able to amplify only a single TCR␤ gene rearrangement, suggesting that only one of the rearranged alleles was expressed. Also, in all cases, the TCR␤ gene rearrangement produced an in-frame TCR␤ transcript.
Expression of SCL and LMO1 in the cell lines
We used Northern blot analysis to verify ongoing expression of SCL and LMO1 in the cell lines (Figure 2) . While we were able to detect LMO1 mRNA expression in all nine cell lines analyzed, surprisingly, we did not detect SCL mRNA in two of the cell lines, 6472/3 and 7114/1 (Figure 2 ). We were also unable to detect SCL mRNA or protein expression in these two cell lines by RT-PCR or Western blot (data not shown). A number of interesting features were observed as these cell lines became established. Initially, there seemed to be two distinct populations of cells in the tissue culture flasks, a tightly adherent stromal layer, and a lymphoblast-like population loosely attached to the stromal layer. With time, an increasing number of suspension cells were noted, suggesting that these cells were now independent of the stromal layer. Interestingly, the established cell lines were all aneuploid, while all of the primary malignancies studied were either diploid or pseudodiploid. Although we did not directly compare the onset of aneuploidy with the ability of the cells to proliferate independently of a stromal layer, it seemed that these two events were temporally related.
As anticipated, the established SCL/LMO1 cell lines were tumorigenic in vivo. Although injected intraperitoneally, the cells often seemed to 'home' to lymphoid tissue, perhaps reflecting the presence of lymphoid adhesion molecules. The observation that clonal TCR␤ gene rearrangements were often different in the SCL/LMO1 cell lines to those in the primary tumors was initially surprising. However, in retrospect, several of the cell lines were clearly biclonal at diagnosis; therefore, it is not surprising that one clone (not always the predominant clone present at initial diagnosis, see Figure 1 ) would eventually gain a growth and/or survival advantage in vitro.
Although the majority of the SCL/LMO1 cell lines displayed persistent expression of both SCL and LMO1 mRNA and/or protein, two cell lines had low or no detectable SCL expression. These cell lines that lacked SCL expression remained tumorigenic. A similar phenomenon involving MYC transgenic mice has been described recently. 20 Mice that overexpressed MYC in the thymus under the control of a tetracycline-regulatable promoter developed T cell tumors, which in most cases regressed when MYC expression was downregulated by the addition of tetracycline. However, a minority of tumors in this study persisted even when the MYC protein was undetectable, leading the authors to speculate that these tumors had undergone additional genetic events rendering them independent of MYC expression. In an analogous fashion, it seems plausible that the SCL/LMO1 cell lines had undergone additional genetic events in vitro which abrogated the requirement for ongoing SCL expression. The observation that all of the SCL/LMO1 cell lines had become aneuploid supports the hypothesis that these cell lines had undergone additional genetic events.
We did not detect any differences between the cell lines established from transgenic mice expressing the full-length and those expressing the truncated SCL protein in any of the parameters tested. Although the sample size was small, this lack of difference between the two SCL isoforms suggests that the amino-terminal portion of SCL is not important in determining the malignant phenotype.
A number of observations suggest that additional genetic events are required before ectopic SCL and LMO1 expression are fully transforming in thymocytes. The gradual rate of clinical disease onset in SCL/LMO1 mice (from 3 to 9 months) suggests that additional, stochastic events must occur before the malignancy becomes clinically apparent. 21 Moreover, thymocytes from 4-week-old SCL/LMO1 transgenic mice are not oncogenic when injected into nu/nu mice, whereas thymocytes from 12-week-old SCL/LMO1 mice are tumorigenic. 9 While we do not know what genes or sets of genes need to become activated and/or inactivated for a frank malignancy to develop, we suspect that a limited number of pathways will be involved. For instance, p15 and p16 are frequently inactivated in human T cell malignancies, by either homozygous deletion or methylation (for review, see Refs 22 and 23). We have detected homozygous deletion or methylation of p16 in a minority of SCL/LMO1 tumors, and several of the SCL/LMO1 cell lines show heavy methylation of the p16 promoter (DHL and PDA, unpublished data).
Extrapolating findings from cell lines to primary malignancies must be done with caution, and the data presented here reinforce this premise, as differences between the cell lines and primary tumors in terms of DNA ploidy, TCR␤ gene rearrangements and immunophenotype were evident. These differences from the primary malignancies suggests additional genetic changes and/or selection of highly malignant subpopulations has occurred. However, this panel of T-ALL cell lines we have established do retain important features of the primary malignancy including SCL and LMO1 integration and expression in the majority of cell lines, a T lymphocyte immunophenotype, and clonal TCR␤ gene rearrangements. We think that these cells may be useful for a variety of purposes. They can serve as an inexhaustible source for proteins and mRNAs which are expressed in thymocytes. They can be used to screen new drugs for activity against T cell malignancies. Also, given that additional genetic events are likely to be required for production of a frank malignancy, with the advent of microarray technology, these cell lines can be surveyed to determine which genes have become reproducibly activated or inactivated during leukemogenesis.
